Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy

2006 ◽  
Vol 248 (1-2) ◽  
pp. 56-61 ◽  
Author(s):  
Zoran Todorović ◽  
Eleonora Džoljić ◽  
Ivana Novaković ◽  
Duško Mirković ◽  
Radan Stojanović ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Mthfr C677t ◽  
Serum Levels ◽  
Levodopa Therapy

scholarly journals Impact of levodopa treatment in the voice pattern of Parkinson’s disease patients: a systematic review and meta-analysis

CoDAS ◽  
2018 ◽  
Vol 30 (5) ◽  
Author(s):  
Patrícia Pinho ◽  
Larissa Monteiro ◽  
Maria Francisca de Paula Soares ◽  
Lorena Tourinho ◽  
Ailton Melo ◽  
...  
Keyword(s):  
Systematic Review ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Acoustic Analysis ◽  
Meta Analysis ◽  
Speech Disorders ◽  
Levodopa Therapy ◽  
Eligibility Criteria ◽  
Perceptual Analysis ◽  
Vocal Intensity

Abstract Purpose Investigate the association between levodopa therapy and vocal characteristics in Parkinson’s disease patients. Search strategy Studies published at MEDLINE, LILACS, and SciELO, from 1960 to December 2016. A systematic review and meta-analysis was performed using the following keywords: Parkinson’s disease; levodopa; L-dopa; voice; speech disorders; dysphonia; dysarthria. After analyzing titles and abstracts, two independent reviewers selected all clinical trials that met the eligibility criteria and selected the articles and the data recorded in a previously standardized table. Selection criteria Trials published in English between 1960 and December 2016 individuals with clinical diagnosis of Parkinson’s disease; use of levodopa therapy in stable doses; acoustic analysis combined or not with auditory-perceptual analysis to evaluate the vocal parameters under investigation. Data analysis The following vocal parameters were analyzed: fundamental frequency (F 0), jitter, and vocal intensity. Standardized mean differences (SMD) were calculated using the Comprehensive Meta-analysis V2 software. Results Nine articles met the eligibility criteria and were selected, with a total of 119 individuals. From these, six articles with 83 individuals were included in the meta-analysis. During the levodopa therapy “on” state, modifications in F 0 (SMD=0.39; 95% CI - 0.21-0.57) and jitter (SMD=0.23; 95% CI - 0.02-0.45) were observed. Vocal intensity was not affected (SMD=0.09; 95% CI - 0.22-0.39) by levodopa ingestion. Data of the included studies were controversial in the auditory-perceptual analysis of voice. Conclusion Levodopa therapy modifies F0 and jitter. No changes in vocal intensity were observed in either the “on” or “off” states of levodopa therapy.

scholarly journals Serum Adiponectin Levels in Advanced-Stage Parkinson's Disease Patients

2011 ◽  
Vol 2011 ◽  
pp. 1-6
Author(s):  
Erica Cassani ◽  
Raffaella Cancello ◽  
Ferruccio Cavanna ◽  
Sabrina Maestrini ◽  
Anna Maria Di Blasio ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cardiovascular Risk ◽  
Body Weight Loss ◽  
Serum Levels ◽  
Normal Weight ◽  
Morbidly Obese ◽  
Serum Concentrations ◽  
Status Assessment ◽  
Young Subjects

Patients with advanced Parkinson's disease (PD) experience body weight loss and reductions in the most common cardiovascular risk factors. At present, the pathogenetic mechanisms involved have not been elucidated. Increased serum concentrations of adiponectin, which possesses antiatherogenic and anti-inflammatory properties, are associated with a reduction in cardiovascular risk. The objective of this study was to determine adiponectin serum concentrations in PD patients. Thirty PD patients underwent a full nutritional status assessment, including the determination of adiponectin serum concentrations. Mean ± SD adiponectin concentrations were 9.59 ± 5.9 μg/mL (interquartile range: 5.92–12.9 μg/mL). In PD patients, adiponectin serum levels were similar to those in normal-weight, healthy, young subjects and significantly higher than that in an aged-matched group of morbidly obese subjects. Further studies are warranted to establish the role of adiponectin in the management of PD patients.

Factors Predictive of the Need for Levodopa Therapy in Early, Untreated Parkinson's Disease

1995 ◽  
Vol 52 (6) ◽  
pp. 565-570 ◽  
Author(s):  
M. P. McDermott ◽  
J. Jankovic ◽  
J. Carter ◽  
S. Fahn ◽  
S. Gauthier ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Levodopa Therapy

The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's disease

2018 ◽  
Vol 71 (2) ◽  
pp. 206-212 ◽  
Author(s):  
Erinaldo Ubirajara Damasceno dos Santos ◽  
Tiago F. Sampaio ◽  
Aléxia D. Tenório dos Santos ◽  
Fernanda C. Bezerra Leite ◽  
Ronaldo C. da Silva ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Levodopa Therapy ◽  
Sporadic Parkinson’S Disease

Higher serum levels of pro-hepcidin in patients with Parkinson’s disease treated with deep brain stimulation

2018 ◽  
Vol 684 ◽  
pp. 205-209 ◽  
Author(s):  
J. Kwiatek-Majkusiak ◽  
M. Geremek ◽  
D. Koziorowski ◽  
R. Tomasiuk ◽  
S. Szlufik ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Deep Brain Stimulation ◽  
Brain Stimulation ◽  
Serum Levels ◽  
Deep Brain
Sign in / Sign up

Export Citation Format

Share Document